Randomized, Blinded, Positive-controlled Phase Ib Clinical Trial for Preliminary Evaluation of Safety and Immunogenicity of Recombinant Pneumococcal Protein Vaccine in Adults Aged 50 Years and Older After Vaccination
Latest Information Update: 09 Dec 2024
At a glance
- Drugs Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections; Respiratory tract disorders; Respiratory tract infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Tianjin CanSino Biotechnology
Most Recent Events
- 09 Dec 2024 Last checked against ClinicalTrials.gov record.
- 04 Dec 2024 Status changed from active, no longer recruiting to completed.
- 19 Oct 2023 Planned End Date changed from 11 Sep 2023 to 11 Dec 2023.